Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies
Company also completes execution of exclusive License Agreement with Yale University
FARMINGTON, Conn., Dec. 07, 2022 (GLOBE NEWSWIRE) — RIGImmune Inc., a biopharmaceutical company developing a new class of RNA immunotherapeutics, today announced new funding support from the Bill & Melinda Gates Foundation to advance the company’s RNA stem loop therapeutics platform for the treatment and adjuvancy of respiratory illnesses caused by RNA viruses. RIGImmune is one of the first development companies to receive an Accelerator Program-Related Investment (“PRI”) from the Bill & Melinda Gates Foundation Strategic Investment Fund. This new funding is additional to a Gates Foundation grant award that RIGImmune received last year to initiate its work in targeting its stem loop molecules for influenza to create broad spectrum host targeted antivirals.
“This new program-related investment from the Gates Foundation will enable RIGImmune to accelerate our efforts to develop effective treatments and potential vaccine adjuvants for influenza and other respiratory disease caused by RNA viruses,” said Susan Sobolov, Ph.D., president of RIGImmune Inc. …